米他匹伐代谢重编程人β-地中海贫血红系祖细胞并增强其对氧化的反应性
本研究以β-地中海贫血患者CD34+来源的体外红系祖细胞为对象,发现其持续表达PKR与PKM2两种丙酮酸激酶亚型;米他匹伐激活PKR和PKM2后促进代谢重编程,提高ATP等高能磷酸化合物水平,并降低氧化标志物,支持其对β-地中海贫血红系造血具有保护作用。
要点
- β-地中海贫血患者CD34+来源红系祖细胞持续表达PKR和PKM2两种丙酮酸激酶亚型。
- 米他匹伐激活PKR和PKM2,提高β-地中海贫血红系祖细胞ATP等高能磷酸化合物水平。
- 米他匹伐降低β-地中海贫血红系祖细胞氧化标志物,改善其成熟与存活。
核心结论
- 米他匹伐对β-地中海贫血红系造血具有保护作用,该作用得益于其对持续表达的PKR和PKM2的激活。
- 除能量代谢获益外,米他匹伐治疗减轻了β-地中海贫血红系造血中的氧化损伤,改善红系祖细胞成熟与存活。
研究设计与样本
- 体外研究,比较β-地中海贫血患者(codb039)与健康对照的CD34+来源红系祖细胞。
主要发现
- 与健康细胞相比,β-地中海贫血患者CD34+来源红系祖细胞持续表达PKR和PKM2两种丙酮酸激酶亚型。
- 米他匹伐激活PKR和PKM2后,β-地中海贫血红系祖细胞高能磷酸化合物水平升高,包括ATP和三磷酸核苷池。
- 蛋白质组学分析显示PKR蓄积,提示米他匹伐可能对丙酮酸激酶稳定性有有益影响。
- ATP可利用性增加伴随蛋白质磷酸化程度升高,尤其涉及细胞周期调控蛋白在转录、翻译和翻译后水平。
- 米他匹伐治疗后β-地中海贫血红系祖细胞氧化标志物减少,包括半胱氨酸氧化翻译后修饰、热休克蛋白70和过氧化物还原酶2表达下调,以及后者氧化还原依赖性亚细胞分布正常化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-thalassemia (β-thal) is a worldwide hereditary red cell disorder characterized by severe chronic anemia. Recently, the pyruvate kinase (PK) activator mitapivat has been shown to improve anemia and ineffective erythropoiesis in a mouse model of β-thal and in patients with non-transfusion-dependent thalassemia. Here, we showed that in vitro CD34+-derived erythroblasts from patients with β-thal (codb039) are characterized by persistent expression of 2 PK isoforms, PKR and PKM2, compared with healthy cells. Activation of PKR and PKM2 via mitapivat promoted significant metabolic reprogramming of β-thal erythroblasts, resulting in higher levels of high-energy phosphate compounds, including adenosine triphosphate (ATP) and triphosphate nucleoside pools. Proteomics analyses revealed an accumulation of PKR, suggesting a possible beneficial effect of mitapivat on the stability of PKs. Increased ATP availability was accompanied by a higher degree of protein phosphorylation, especially in proteins involved in cell cycle regulation at the transcriptional, translational, and posttranslational levels, supporting the effect of mitapivat on erythroid maturation. Upon treatment with mitapivat, β-thal erythroblasts showed decreased markers of oxidation, including cysteine oxidative posttranslational modifications, downregulation of heat shock protein 70 and peroxiredoxin-2 expression, and normalization of the redox-dependent subcellular distribution of the latter enzyme. Collectively, our data support a protective effect of mitapivat in β-thal erythropoiesis, an effect favored by its activation of persistently expressed PKR and PKM2. In addition to the anticipated benefits on energy metabolism, we report that mitapivat treatment mitigated the oxidative damage in β-thal erythropoiesis, ensuring improved β-thal erythroblast maturation and survival.
引用
- Siciliano A, D'Alessandro A, Matte A, et al. Mitapivat metabolically reprograms human β-thalassemic erythroblasts, increasing their responsiveness to oxidation. Blood Adv. 2025. PMID: 40085946. doi:10.1182/bloodadvances.2024013591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。